We are interested in studying molecular abnormalities that underlie diseases to design targeted molecular therapies. Specifically, alterations in the regulation and protein: protein interaction due to mutations are implicated from cardiovascular disease to cancer. Understanding the structural and mechanistic details of each signaling event and the protein-protein interactions involved is our key to design the next generation of targeted therapies.